We’ll help you find the highest quality medicine that you need.
Xeljanz
is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).
Manufactured by: Pfizer, Inc
Active Ingredient(s): Tofacitinib Citrate
Dosage Form: Tablet, oral
Strength: 5 mg
FDA approved: November 6, 2012
More information about Xeljanz
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203214s000lbl.pdf